November 2000 – The CenterWatch Monthly : Volume 7, Issue 11, November 2000

Grant Market to Exceed $4 Billion in 2000

Total clinical grant spending, from all sources, will exceed $4 billion in 2000. More than 80% of spending on clinical trial grants will come from industry sources. PhRMA member companies, the largest sponsor segment, will spend $2.36 billion in grants to investigative sites.

CenterWatch market size analyses now include estimates of government funding for comparable clinical trial activity. The NIH will spend more than $700 million in grants to investigators conducting clinical trials in 2000.

Turning 'Registry' Trials Up a Notch

Regulatory and market pressures are pushing sponsors to conduct larger numbers of observational registry trials to gather data on approved medical therapies among patients in real-use settings.

Although registry trials pay relatively small contract and grant fees, revenue from these trials is expected to grow as the number of patients and project scope expand.

CentreStage Europe: Multinational Trials Bolstered by Technology

The advent of communication and management technologies, combined with the standardization of the ICH guidelines and reciprocal regulatory acceptance, has opened the door for increasing numbers of global trials. Frank Garnham, director of business development at Chiltern, a privately held, U.K.-based CRO, says Chiltern's number of multinational trials has roughly tripled in the last five years. Hassan Movahhed, senior director clinical affairs at Amgen, said that 80% of Amgen's studies are multinational, and Helen Davis, a senior vice president with global responsibilities at Quintiles, has seen an increase in Quintiles' number of global trials in the nearly 10 years she has been at the company.

Eye On: Contraception

AlthougOne of the most dynamic areas of women's health research is the field of contraception. There are many new oral birth control formulations in the works, along with the development of an array of new delivery systems and methods for effective and safe contraception. CenterWatch has identified 15 drugs in the clinical research pipeline representing an estimated $65 to $75 million clinical grants market. The new delivery systems include immunocontraceptives, transdermal contraceptives, new forms of contraceptive pills and barrier contraceptives, and implantable rods.

• Month in Review
• Opportunities Underway
• TrialWatch